Novo Nordisk will target launches of its popular obesity shot Wegovy in markets where it already has strong sales of its older weight-loss drug Saxenda, CEO Lars Fruergaard.
Novo Nordisk will more than double supplies of lower doses of its obesity drug Wegovy in the United States compared with recent months, CEO Lars Fruergaard Jorgensen said on.
The Danish drugmaker is working to convince European governments and insurers to reimburse the drug, seeking to position it as more than a lifestyle drug. Wegovy was launched in the U.S. in June 2021 but it took Novo until December 2022 to make all doses available there because of an initial production problem.
LONDON (Reuters) -The EU's drug regulator said on Friday it would continue to review whether Novo Nordisk's popular weight-loss drug Wegovy could also be used in some cases to reduce the risk of strokes and heart attacks. The expert panel assessing Novo's request to include certain heart benefits in the product's label did not adopt an opinion, a spokesperson for the regulator said. "The application is still under review and we cannot speculate on when it will conclude," he added.
LVMH results prompt $70 billion buying spree in luxury shares By Mimosa Spencer PARIS (Reuters) -Investors dived back into top luxury shares on Friday, adding some $70 billion to their market value as LVMH’s latest sales figures reassured investors about the sector’s resilience to economic headwinds, particularly in China. The buying spree helped recoup some […]